Clinical Trials for Childhood Brain Stem Glioma

Trials 1-8 of 8

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Status: Active
Location: 15 locations
A Peptide Vaccine (PEP-CMV) for the Treatment of Pediatric Patients with Newly Diagnosed High-Grade Glioma and Diffuse Intrinsic Pontine Glioma, or Recurrent, Refractory, or Progressive Medulloblastoma
Status: Active
Location: 4 locations
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Status: Active
Location: 3 locations
Ribociclib and Everolimus Following Radiotherapy in Patients with High-Grade Glioma, and Diffuse Intrinsic Pontine Glioma, Harboring Cell Cycle and/or PI3K/mTOR Pathway Genetic Changes (A TarGeT Treatment Trial)
Status: Active
Location: 2 locations
Atovaquone Alone or Combined with Radiation for the Treatment of Children with Malignant Brain Tumors
Status: Active
Location: 2 locations
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma
Status: Active
Location: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
B7-H3-Specific CAR T Cell Therapy (Loc3CAR T Cells) for the Treatment of Pediatric Patients with Primary Central Nervous System Tumors
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Testing the Safety, Tolerability and Immunological Effects of SurVaxM in Children and Young Adults with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Status: Temporarily Closed to Accrual
Location: 13 locations